Zacks Research Has Optimistic Outlook of ResMed Q1 Earnings

ResMed Inc. (NYSE:RMD) – Stock analysts at Zacks Research lifted their Q1 2026 EPS estimates for shares of ResMed in a report issued on Monday, July 14th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.40 per share for the quarter, up from their prior estimate of $2.37. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q2 2026 earnings at $2.49 EPS, Q3 2026 earnings at $2.52 EPS, FY2026 earnings at $9.87 EPS, Q1 2027 earnings at $2.53 EPS, Q2 2027 earnings at $2.64 EPS and Q3 2027 earnings at $2.74 EPS.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $2.36 by $0.01. The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.28 billion. ResMed had a net margin of 26.15% and a return on equity of 25.67%. The business’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.13 EPS.

Other analysts have also recently issued reports about the company. Wall Street Zen cut ResMed from a “buy” rating to a “hold” rating in a research note on Saturday, May 24th. KeyCorp set a $274.00 price objective on shares of ResMed in a report on Thursday, April 24th. UBS Group decreased their price objective on shares of ResMed from $290.00 to $285.00 and set a “buy” rating for the company in a report on Thursday, April 24th. JPMorgan Chase & Co. upped their price objective on shares of ResMed from $286.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, April 24th. Finally, Piper Sandler decreased their price objective on shares of ResMed from $260.00 to $248.00 and set a “neutral” rating for the company in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $263.00.

ResMed Stock Performance

Shares of NYSE:RMD opened at $254.00 on Wednesday. The company has a current ratio of 3.41, a quick ratio of 2.49 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average price of $251.02 and a 200-day moving average price of $237.14. The company has a market cap of $37.24 billion, a price-to-earnings ratio of 28.51, a price-to-earnings-growth ratio of 1.58 and a beta of 0.77. ResMed has a 12 month low of $196.43 and a 12 month high of $263.05.

Institutional Trading of ResMed

Institutional investors and hedge funds have recently made changes to their positions in the company. Ballentine Partners LLC raised its holdings in shares of ResMed by 6.3% in the first quarter. Ballentine Partners LLC now owns 1,782 shares of the medical equipment provider’s stock valued at $399,000 after acquiring an additional 105 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in ResMed by 384.8% in the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in ResMed by 393.0% in the first quarter. Exchange Traded Concepts LLC now owns 2,529 shares of the medical equipment provider’s stock worth $566,000 after purchasing an additional 2,016 shares in the last quarter. EntryPoint Capital LLC bought a new position in ResMed in the fourth quarter worth about $347,000. Finally, MML Investors Services LLC raised its holdings in ResMed by 31.9% in the fourth quarter. MML Investors Services LLC now owns 11,468 shares of the medical equipment provider’s stock worth $2,623,000 after purchasing an additional 2,771 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Insider Activity at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $242.25, for a total transaction of $484,500.00. Following the completion of the transaction, the director directly owned 71,218 shares of the company’s stock, valued at $17,252,560.50. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction on Monday, July 7th. The stock was sold at an average price of $256.72, for a total value of $2,056,070.48. Following the sale, the chief executive officer owned 455,503 shares of the company’s stock, valued at approximately $116,936,730.16. This trade represents a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,013 shares of company stock valued at $7,238,913. 0.71% of the stock is owned by corporate insiders.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Investors of record on Thursday, May 8th were issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend was Thursday, May 8th. ResMed’s dividend payout ratio (DPR) is presently 23.79%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.